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Carotid endarterectomy (CEA) is the gold-standard management for secondary stroke prevention
yet carotid artery stenting (CAS) has emerged in the last decade as an alternative for high surgical
risk patients.
Purpose: To assess the effectiveness, safety and outcomes of CAS in extra-cranial carotid artery
stenosis patients in terms of stroke prevention.
Methodology: Twenty patients with symptomatic and asymptomatic carotid artery stenosis were
enrolled between 2012 and 2014. Symptomatic patients were eligible for CAS if the internal carotid
artery stenosis was P50%, while 80% was the threshold in asymptomatic patients.
Results: Symptomatic patients enrolled were fifteen (75%) and asymptomatic patients were five
(25%). Two patients (10%) were excluded owing to target vessel occlusion. One patient (5%)
underwent bilateral CAS. The procedure was successful in eighteen patients (90%) one of them
complicated by distal embolization (5%). One patient died secondary to associated chronic liver
disease (5%), otherwise no stroke or death was recorded along the follow-up period.
Conclusion: Careful patient selection and technique optimization are crucial to improve clinical
outcome which make it a safe alternative for surgical revascularization in stroke prevention.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
Stroke is the third most common cause of death in industrial-
ized nations, after myocardial infarction and cancer. It is thesingle most common reason for permanent disability.
Approximately 1 in 4 people die within 1 year after having an
initial stroke (1). Moreover, 30–50% of stroke survivors do
not regain functional independence and 15–30% of all stroke
survivors are permanently disabled (i.e., not able to walk, talk
clearly, or feed themselves with a favored hand). Thus stroke
demands a massive financial and personal burden on our soci-
ety (2). Approximately 25% of ischemic strokes are secondary
to extracranial carotid artery occlusive disease. Carotid artery
Table 1 Study group clinical presentation and associated comorbidities.
Age (range, mean ± SD) 45–75 years & mean age 60.8 ± 7.8
Men 17 (85%)
Smoking – current or past 12 (60%)
Symptomatic ICA/CCA stenosis 15 (75%)
Previous stroke 10 (50%)
TIA 4 (20%)
Amaurosis fugax 1 (5%)
Diabetes mellitus 8 (40%)
Arterial hypertension 12 (60%)
Peripheral arterial disease 4 (20%)
History of myocardial infarction 5 (25%)
Significant bilateral ICA disease 3 (15%)
High risk lesion 14 (70%) (Near total ‘string-sign’ stenoses; 9 (45%) & ulcerated plaque; 5 (25%))
Others 1 (5%) with hepatocellular carcinoma
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asymptomatic stenosis of >50% (3), with a higher prevalence
among patients with heart disease (18.2%) or concomitant
hypertension and heart disease (22.1%). The prevalence is even
higher among patients with acute strokes, with up to 60% hav-
ing carotid stenosis on duplex ultrasonography (4). The carotid
stenosis related stroke risk is dependent on the stenosis severity,
patient symptom, and specific lesion characteristics. Symp-
tomatic patients who have had stroke or transient ischemic
attack within the previous 6 months, have a much higher stroke
risk than do asymptomatic individuals (5).
Antiplatelet therapy of carotid disease reduces the incidence
of stroke (6), yet several studies have demonstrated that caro-
tid endarterectomy (CEA) is more effective than medical ther-
apy alone for both symptomatic and asymptomatic carotid
atherosclerotic disease (including the North American Symp-
tomatic Carotid Endarterectomy Trial (NASCET) (7), Asymp-
tomatic Carotid Atherosclerosis Study (ACAS) (8), and
Asymptomatic Carotid Surgery Trial (ACST) (9)). Endarterec-
tomy has several limitations as the operation carries a signifi-
cant risk of complications, particularly in patients with
multiple comorbidities, and is highly operator dependent (10).
Kerber et al. published the first report of carotid artery bal-
loon angioplasty in 1980 (11). In 1987, Theron et al. published
a larger series including 48 patients with 94% technical success
rate and 4.1% major stroke morbidity (12). By 1995, a world-
wide experience review among 523 patients claimed favorable
results with 96.2% technical success, 2.1% morbidity, 6.3%
transientminor complications, and no deaths (13). Over the past
decade, the intraprocedural use of cerebral protection devices to
guard against micro- or macroembolism has further improved
these outcomes (14) making carotid artery stenting (CAS) an
accepted alternative toCEAfor patients at high surgical risk (15).
This study was constructed to assess the effectiveness and
safety as well as the short- and long-term clinical outcomes
of CAS in management of extra-cranial carotid artery stenosis
including patients with no high surgical risk in terms of stroke
prevention.
2. Patient and methods
2.1. Study group
Twenty patients were enrolled in this study between 2012 and
2014 for carotid artery stenting (Fourteen men and two womenwith age range from 45 to 75 years and mean age 60.8 ± SD
7.8) each of them gave informed written consent to participate.
Symptomatic patients were eligible for CAS if the ICA stenosis
was 50%, while 80% was the stenosis threshold in asymp-
tomatic patients. Lesions were classified as ‘‘high risk” by mor-
phology (Near total ‘‘string-sign” stenoses were nine patients
(45%) and five patients (25%) have ulcerated plaques). The
clinical presentation and associated comorbidities are demon-
strated in Table 1.
2.2. Imaging
All patients underwentDuplex ultrasound performedwith a lin-
ear 7- to 10-MHz probe to evaluate lesion severity (area and
diameter stenosis) and morphology (echogenicity, the presence
and degree of calcification, or ulceration). Extra- and intracra-
nial CTA (biplanar, 3-dimensional reconstructions with smart
vascular analysis) or contrast enhanced MRA was performed
in selected patients to characterize the target lesion, aortic arch
type, and supra-aortic vessel anatomy and to exclude significant
intracranial pathology as well as evaluation of the collateral cir-
culation. Morphological (semiquantitative) lesion assessment
included fatty, fibrous, and calcium content was depicted.
2.3. CAS procedure
Patients received a dual antiplatelet regimen consisting of
aspirin (100 mg daily) and clopidogrel (75 mg daily) at least
3 days before the stenting. A loading dose of clopidogrel
(300–600 mg) administered early on the day of the procedure
was an alternative for patients who are already taking aspirin.
The patient receives an intravenous loading dose of heparin
(50–70 U/kg) with activated clotting time of 250–300 s is main-
tained throughout the procedure. During the procedure
patient was under ECG monitoring due to potential bradycar-
dia and blood pressure monitoring for possible hypotension
related to carotid sinus stimulation by balloon inflation.
Procedures were done under the image guiding of (Artis zee
Flat Detector Biplane-Angiosuite, Siemens, Forchheim, Ger-
many). The vascular access via the femoral artery was the
approach that was employed. Femoral artery was punctured
using a Seldinger needle and then 6–8 F sheath was placed
under local anesthesia.
Angiography of the aortic arch was often performed prior
to selective carotid angiography in order to identify possible
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exchange the typically employed diagnostic catheters for an
alternative one. After engaging the common carotid artery,
standard angiographic projections for demonstrating the caro-
tid bifurcation (anteroposterior, lateral and ipsilateral anterior
oblique (30–45) projection) were obtained. Four-vessel
angiography was conducted to visualize the intracranial vessels
and show the status of collateral arteries.
Once the anatomy of the target vessel has been identified,
an exchange-length 0.035-in. wire was inserted under road
mapping into the ECA. The diagnostic catheter was exchanged
over the wire for a 90-cm, 6-to 8-Fr guiding catheter that is
then advanced into the common carotid artery (CCA) below
the bifurcation.
Predilatation of the stenosis was needed in selected patients
to provide better passage of protection devices and positioning
of the stent. An exchange length 0.014-in. microguidewire
(Transcend 300 Floppy microwire; Boston Scientific, Fremont,
CA, USA) was used for navigation and dilatation was done by
using a small angioplasty balloon 3 mm (Fairway Balloon-
IHT, Barcelona, Spain) with short inflation time of 5–10 s.
The procedures were done under the cerebral protection of dis-
tal filter (SpideRxTM-EV3, Plymouth, MN, USA) which was
introduced into the vascular segment distal to the stenosis.
The stent was selected according to the ICA course: a
closed-cell stent (Wallstent-Monorail, Boston Scientific,
Fremont, CA, USA) was used in a straight course, and an
open-cell stent (Prote´ge´ RX-EV3, Plymouth, MN, USA) was
used in a tortuous course. Post-dilation of the stent was
performed after stent deployment using a 4–6-mm balloon
in selected patients with slow and gradual inflations (each
10–60 s at 6–20 atmospheres).
Following post-dilation of the stent, angiography of the
carotid arteries and intracranial vessels was carried out to rule
out cerebral embolism. Patients who underwent CAS were
monitored in the intensive care unit for 24 h with continuous
blood pressure, oxygen saturation, and electrocardiographic
monitoring and underwent a neurological examination hourly.
Antihypertensive agents were used as needed to maintain sys-
tolic blood pressure 140 mmHg after CAS. Patients who show
no additional neurological deficits after CAS were discharged
within 3 days after CAS with 75 mg/day clopidogrel and
100 mg/day aspirin continued for 6 months after CAS.
2.4. Follow-up
A follow-up color duplex ultrasound scan and neurological
examination were conducted for all patients at 1 month after
the intervention to verify the acute result of the procedure,
and at 3, 6 and 12 months to rule out ischemic insults.
3. Results
3.1. Interventional results
Symptomatic patients enrolled in the study were fifteen (75%)
and asymptomatic patients were five (25%). Two patients
(10%) were excluded owing to target vessel occlusion. One
patient (5%) underwent bilateral carotid artery stenting. Stents
were successfully inserted in 18 of 20 patients (90%). Distal
cerebral protection was used in all patients using distal filter(SpideRxTM-EV3, Plymouth, MN, USA.). Four patients
(20%) needed pre-dilation to pass the distal filter. No
additional pre-dilation of the stenosis was needed for stent
deployment after installing the filter. Closed cell stents
(Wallstent-Monorail, Boston Scientific, Fremont, CA, USA)
were implanted in 15 patients (75%) (Fig. 1), and an open-
cell stents (Prote´ge´ RX-EV3, Plymouth, MN, USA) were
implanted in 3 patients (15%) presented with curved ICA
(Fig. 2). Additionally, 8 patients (40%) required post-dilation
after placing the stent. The results are summarized in Table 2.
The criteria for carotid artery near occlusion were used
(16): Obvious reduced diameter of the ICA compared with
the opposite ICA or the ipsilateral ECA and delayed cranial
arrival of ICA contrast compared with that of the external car-
otid artery (ECA). Bilateral CAS was done for bilateral tight
stenosis in one patient (5%) with one week interval.
Transient hemodynamic alterations such as hypotension
and bradycardia were observed in three patients (15%) during
and/or after balloon inflation which were recovered by intra-
venous 1 mg atropine administration. No major vascular
access site complications were recorded.
Intra-procedural vascular events occurred in one patient
(5%) who was presented by sensory aphasia and right hemi-
paresis secondary to ischemic infarction affecting the left fron-
toparietal watershed zone and tight left ICA stenosis. After
implantation of the stent, thromboembolism occluding the left
MCA was encountered (Fig. 3). It was managed by self
expanding stent (Solitaire FR, EV3, Plymouth, MN, USA)
and angioplasty balloon 2 mm (Fairway Balloon-IHT,
Barcelona, Spain). The patient shows full recovery with no
superadded neurological deficits.
3.2. Follow-up results
All patients received regular clinical follow-up of at least
6 months. Among these, only one patient died (5%) secondary
to associated liver cell failure and hepatocellular carcinoma.
All other patients didn’t develop any new neurological symp-
toms. No significant intimal hyperplasia by follow-up color
Doppler scan was detected. No cases developed myocardial
infarction along the follow-up period.
4. Discussion
Carotid artery stenting (CAS) has steadily developed during
the past decade as an alternative to CEA for patients who
would benefit from surgical treatment. Percutaneous CAS
offers several potential advantages, including the avoidance
of general anesthesia, neck incision, and the risk of cranial
or cutaneous nerve damage from the surgical incision (17).
Large randomized trials in the 1980s and 1990s for CEA as
management of carotid artery stenosis contained strict eligibil-
ity criteria and excluded many patients commonly found in
clinical practice. These exclusion criteria include anatomic
and physiologic ‘‘high-risk” criteria, such as age, previous sur-
gery, uncontrolled diabetes or hypertension, kidney or liver
failure, and heart valve or rhythm disturbance. The presence
of such comorbidities has a significant negative effect on
outcome after CEA, and they have served as the basis for
subsequent implementation of CAS as an alternative treatment
to CEA in clinical practice (18–20).
Fig. 1 67 years old male patient with history of right side hemiplegia. Digital subtraction angiograms. (A & B) Right common carotid
artery (CCA) injection, AP & lateral views show internal carotid artery stenosis (50%) with ulcerating thrombus. (C & D) Left common
carotid artery (CCA) injection, AP & lateral views show totally occluded left internal carotid artery. (E & F) After deployment of the stent
(Wallstent-Monorail, Boston Scientific, Fremont, CA, USA) under the cerebral protection of the distal filter (SpideRxTM-EV3, Plymouth,
MN, USA). (G & H) Final angiographic result after implantation of the stent.
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CAS including stroke, myocardial infarction and death. The
overall perioperative carotid endarterectomy stroke risk and
death was 5.8% in NASCET, 2.3% in ACAS and 3.1% in
ACST (21). However, these trials were conducted using highly
screened surgeons, low-risk patients and high-volume surgical
centers (22), limiting the application of these results to smaller
institutions with wider patient demographics. Combined caro-
tid endarterectomy related stroke and death rates are up to
12.6% have been reported for less highly selected patients
(23), with certain prognostic features imposing an even poorer
outcome (age >75 years, coronary artery disease or contralat-
eral internal carotid artery occlusion) (24).
Over the past decade, carotid artery stenting (CAS) has
become an accepted alternative to CEA for patients at high
surgical risk, and more recently has shown similar outcomes
for patients at standard risk. Multiple carotid registries sum-
marized in Table 3 have been done to improve the outcome
and optimize the indication.The Carotid Revascularization Endarterectomy versus
Stenting Trial (CREST) is the largest trial comparing the
CAS and CAE results. It is a multicenter, prospective random-
ized clinical trial initially designed to compare CEA with CAS
in only symptomatic patients. Target enrollment was powered
at 2500–3000 patients, but trial was revised to include patients
with asymptomatic carotid stenosis. The trial eventually
enrolled 1321 symptomatic and 1181 asymptomatic patients.
The primary endpoint included periprocedural (30 days)
death/stroke/MI, as well as any subsequent stroke ipsilateral
to the carotid intervention during a 4-year follow-up window.
The summary findings of this trial, published in 2010 in the
New England Journal of Medicine (31), demonstrated no dif-
ference between CEA and CAS in the composite endpoint of
death/stroke/MI (CAS 7.2% versus CAE 6.8%). However,
stroke occurred more frequently following CAS (CAS 4.1%
versus CAE 2.3%) and MI occurred more frequently following
CEA (CAS 1.1% versus CAE 2.3%). Late ipsilateral stroke
rates were slightly higher following CAE (CAS 2% versus
Fig. 2 60 years male patient with history of recurrent transient ischemic attacks. Digital subtraction angiogram. (A) Left common
carotid artery (CCA) injection, lateral views, shows internal carotid artery stenosis (70%) with ulcerating thrombus (arrow). (B) After
deployment of the stent (Prote´ge´ RX-EV3, Plymouth, MN, USA). (C) Final angiographic result after implantation of the stent.
Table 2 Summary of the results.
Failed procedure 2 (10%)
Stent type Closed cell design: 15
(75%)
Open cell design: 3 (15%)
Predilatation 4 (20%)
Postdilatation 8 (40%)
Distal embolization 1 (5%)
Sustained hypotension and
bradycardia
3 (15%)
Follow-up stroke or MI 0 (0%)
Follow-up death rate 1 (5%)
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cedural death rates (CAS 0.7% versus CAE 0.3%). In addi-
tion, associated complication like periprocedural cranial
nerve palsies were less frequent with CAS (0.3%) versus
(4.7%) with CEA (32). Subsequently, guidelines based on the
CREST were published, suggesting that CAS was equivalent
to CEA for the symptomatic patient (33) and an alternative
for CAE with selected high-risk patients because of anatomic
or physiologic factors (34).
We tried in our experience to optimize the technique, min-
imize the associated complication and improve the outcome.
All procedures were done under cerebral protection of distal
filters which preserve the flow and have the advantage to per-
form angiogram during the procedure; no filter drawbacks
such as missing small particles, filter thrombosis or ICA spasm
(32) were encountered. Stent selection was depending on steno-
sis severity, angulation in the perilesional carotid segments,
calcification and plaque characteristics; open cell design has
larger free cell area between the stent cell lattices and more
malleable, flexible, and less prone to kinking (35) so it was pre-
served to handle tortuous anatomy while closed cell design ismore rigid and prone to kinking with greater outward radial
force and more effective support to labile plaques (35) which
made it the perfect choice for tight stenosis with straight
course.
Symptomatic distal embolization is the most frequent and
important complication of CAS. It is caused by the release
of material (thrombotic, necrotic, or atherosclerotic) from
the site of the lesion during the intervention (36). Intraproce-
dural distal embolization occurs in one patient in our study
which was treated properly with no residual neurological def-
icits. The contributing risk factors for distal embolization can
be classified into three groups: the first group related to the
carotid lesion itself which may be soft plaque or fresh throm-
bus, the second group related to the medical therapy including
poor pretreatment with double antiplatelet agents or insuffi-
cient heparin during procedure, and the third one related to
the procedure which are aggressive manipulation of the guide
wire, aggressive balloon dilatation prior to or after stent
deployment or unprotected procedure (37). The inventory of
the cathlab should be equipped for such complications by lytic
agents, intracranial retrieval devices (e.g., Phenox Clot Retrie-
ver, Merci Retrieval Device, Penumbra) or intracranial stents
(e.g., Wingspan, Solitaire, Enterprise, Neuroform).
Sustained hypotension and bradycardia have been reported
to occur following 4–11% of carotid stenting procedures and
were not usually associated with any adverse clinical events
in the hospital or during the 30-day follow-up period (38). Sus-
tained hypotension and bradycardia were avoided in our study
by atropine administration at the time of balloon inflation.
Preserved blood pressure at 140 mm/hg was important as a
prophylaxis against intracranial hemorrhage and hyperperfu-
sion syndrome. The long-term follow-up results of CAS in
our study were outstanding with no stroke recurrence and no
cardiovascular complications related to the procedure. The
single cause of death in our study was secondary to associated
liver disease and hepatocellular carcinoma.
Fig. 3 65 year old male patient with history of right side hemiparesis and sensory aphasia. (A & B): axial FLAIR images show ischemic
infarction in the left frontoparietal watershed zone. (C & D) Left common carotid artery DSA, (A-P & lateral) views show tight stenosis at
the proximal ICA. (E) Anteroposterior DSA demonstrates the predilatation balloon (Fairway Balloon-IHT, Barcelona, Spain (3 mm)).
(F) Lateral DSA After deployment of the stent (Wallstent-Monorail, Boston Scientific, Fremont, CA, USA) and inflation of the balloon
(Fairway Balloon-IHT, Barcelona, Spain (4.5 mm)). (G) Final angiographic result after implantation of the stent. (H & I) Left MCA
angiogram (A-P & lateral) views show filling defect at the bifurcation of M2 segment with occluded superior division. (J & K):
Angiographic results after deployment of (Solitaire FR, EV3, Plymouth, MN, USA) stent and inflation of angioplasty balloon 2 mm
(Fairway Balloon-IHT, Barcelona, Spain).
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patients, absence of a control group and relatively short
follow-up period. But we confirmed CAS results in
symptomatic and asymptomatic patients with a carotid arterydisease and identified CAS as a technically feasible and effec-
tive method for preventing stroke, not necessarily limited to
high risk patients by displaying our results and some others
in the previous literature.
Table 3 30 day complication rates in carotid artery stenting registries enrolling more than 1000 patients.
Name Year No EPD (%) Sympt. patient % Surgical high risk D/S/MI (%) S (%)
CAPTURE (25) 2007 3500 100 14 Yes 6.3 5.7
CASES PMS (26) 2007 1493 100 22 Yes 5.0 4.5
PRO-CAS (27) 2008 5341 75 55 No NA 3.6
SAPPHIRE (28) 2009 2001 100 28 Yes 4.4 4.0
SVS (29) 2009 1450 95 45 Yes 5.7 NA
EXACT (30) 2009 2145 100 10 Yes NA 4.1
CAPTURE 2 (30) 2009 175 100 13 Yes NA 3.4
CAPTURE; Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare Events. CASES–PMS (Carotid Artery Stenting With
Emboli Protection Surveillance–Post-Marketing Study). Pro-CAS, Prospective Registry of Carotid Artery Stenting. SAPPHIRE: Stenting and
angioplasty with protection in patients at high-risk for endarterectomy. EXACT; Emboshield and Xact Post Approval Carotid Stent Trial
(EXACT).
EPDs, emboli protection devices; sympt, symptomatic; D, death; S, stroke; MI, myocardial infraction.
Efficacy and safety of carotid artery stenting 1915. Conclusion
CAS is a safe alternative for surgical revascularization by CEA
in management of extracranial carotid artery disease and
stroke prevention which should not be limited to high risk
patients only. Careful patient selection and optimization of
the technique are crucial to avoid the complication of CAS
and improve clinical outcome.
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